Abstract:
The present invention relates to a an improved process for the preparation of carbapenem compounds involving the deprotection of a compound of Formula (IV) to form a thiol of Formula (I) which is then further condensed with a compound of Formula (III).
Abstract:
The present invention provides a one-pot process for the preparation of meropenem. The present invention further provides a process for the preparation of meropenem trihydrate.
Abstract:
The present invention relates to a process for the preparation of esters of 2-diazo-3-trimethylsilyloxy-3-butenoic acid which comprises reacting a diazoacetoacetate with iodotrimethylsilane in the presence of an organic base, wherein iodotrimethylsilane is prepared by reacting hexamethyldisilane with iodine. The present invention further relates to converting such esters of 2-diazo-3-trimethylsilyloxy-3-butenoic acid to other compounds, such as a substituted diazoazetidinone, an azetidinone, or a bicyclo ketoester.
Abstract:
The invention relates to N-methylpyrrolidone and N,N-dimethylacetamide solvates of cefprozil. The invention also relates to processes for preparing the solvates of cefprozil, crystalline cefprozil from said solvates and pharmaceutical compositions that include the crystalline cefprozil.
Abstract:
The present invention provides a process for preparing novel intermediates of Formula wherein, R 1 can be hydrogen, C 1 -C 4 alkyl, halogen, nitro, hydroxy, or C 1 -C 4 alkoxy; R x can be selected from hydrophobic residue of HMG-CoA reductase inhibitors; which can be effectively used for the preparation of HMG-CoA reductase inhibitors such as rosuvastatin and pharmaceutically acceptable salts thereof.
Abstract:
The present invention relates to process and intermediates for the preparation of substituted 1,3-oxathiolanes. The present invention specifically relates to a process for the preparation of lamivudine.
Abstract:
The invention relates to solvates of cefprozil. The invention also relates to processes for preparing the solvates of cefprozil, crystalline cefprozil from said solvates and pharmaceutical compositions that include the crystalline cefprozil.